SGLT2 inhibitors suppress renal glucose reabsorption to reduce blood glucose and body weight, alter renal hemodynamics, reduce intraglomerular pressure, attenuate diabetes-associated hyperfiltration, tubular hypertrophy, and tubular toxicity of glucose to directly protect the kidney. This evidence concerns the gene SLC5A2 and diabetes mellitus.